David Hastings

Insider profile

Currently holds a position at SCYNEXIS Inc

Positions

Position Company Period
Director SCYNEXIS Inc Sept. 24, 2015 -
David Hastings's trades of Arbutus Biopharma Corp's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Planned sale
Price
296.45
Quantity 74,128 +6.8%
Value US$1,633,628
Transaction date
Proposed sale
Price
108.05
Quantity 96,700
Value US$1,513,614
Transaction date
Planned sale
Price
443.99
Quantity 1,127 -12.5%
Value US$4,217,762
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-02-05 2025-02-04
PlS Planned sale
74,128 +6.8%
296.45
US$1,633,628 		74,128 +6.8% 296.45 US$1,633,628
2025-02-04 2025-02-04
PrS Proposed sale
96,700
108.05
US$1,513,614 		96,700 108.05 US$1,513,614
2024-02-05 2024-02-02
PlS Planned sale
1,127 -12.5%
443.99
US$4,217,762 		1,127 -12.5% 443.99 US$4,217,762